The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sequentmedical.com

Stage

Acquired | Acquired

Total Raised

$65.1M

Valuation

$0000 

About Sequent Medical

Sequent Medical a privately-held firm developing a new medical device for aneurysm embolisation. Sequent developed the WEB Aneurysm Embolisation System, a minimal invasive brain aneurysm treating implant which has been used on patients worldwide.

Sequent Medical Headquarter Location

11 Columbia

Aliso Viejo, California, 92656,

United States

949-830-9600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sequent Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sequent Medical is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

11,673 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

D

Digital Health

12,999 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

Sequent Medical Patents

Sequent Medical has filed 57 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Fluid dynamics
  • Interventional radiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/22/2020

6/7/2022

Actuators, Metal forming, Engine technology, Structural engineering, Valves

Grant

Application Date

12/22/2020

Grant Date

6/7/2022

Title

Related Topics

Actuators, Metal forming, Engine technology, Structural engineering, Valves

Status

Grant

Latest Sequent Medical News

Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer

Sep 17, 2020

| Source: Inari Medical, Inc. IRVINE, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020. In his expanded role, Mr. Hykes will now have responsibility for Research, Product Development, Manufacturing, Operations, Quality and Regulatory, in addition to the Commercial functions. Prior to Inari, Mr. Hykes served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Prior to Sequent, Mr. Hykes spent twelve years at Medtronic in various roles including the VP of Marketing and VP of Clinical and Regulatory for the AF Solutions business, and Director of Investor Relations. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. He received his B.B.A. from the University of Wisconsin Madison and an M.B.A. from Harvard Business School. “Drew has had a significant impact on our commercial success over the last three years,” said Bill Hoffman, CEO of Inari Medical. “Under Drew’s leadership, we have rapidly built a highly effective and efficient commercial organization dedicated to improving the lives of patients suffering from venous thromboembolism. This promotion not only recognizes this record of accomplishment, but his passion for Inari’s mission.” "It's an honor to continue to help Inari Medical bring new technologies to many more physicians and their patients," said Hykes. “We have built an outstanding organization, with talented people fully dedicated to changing the lives of patients suffering from life-threatening blood clots." About Inari Medical, Inc. Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism. Investor Contact:

  • Where is Sequent Medical's headquarters?

    Sequent Medical's headquarters is located at 11 Columbia, Aliso Viejo.

  • What is Sequent Medical's latest funding round?

    Sequent Medical's latest funding round is Acquired.

  • How much did Sequent Medical raise?

    Sequent Medical raised a total of $65.1M.

  • Who are the investors of Sequent Medical?

    Investors of Sequent Medical include Terumo, U.S. Venture Partners, Versant Ventures, Domain Associates and Delphi Ventures.

  • Who are Sequent Medical's competitors?

    Competitors of Sequent Medical include Broncus Medical, TriVascular Technologies, Veryan Medical, arstasis, Micrus Endovascular and 12 more.

You May Also Like

Veryan Medical Logo
Veryan Medical

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.

R
Reva Medical

Founded in 1998, REVA Medical is dedicated to developing interventional medical devices that leverage the Company's stent designs and biomaterials to improve the treatment of vascular disease. nnThe Company's flagship product is a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product promises to revolutionize the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The Company is also certified to the ISO 13485:2003 standard.

E
Embolic Protection

Devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures. Acquired by Boston Scientific in 2001.

X
XTENT

Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.

S
Satiety

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

D
Devices for Vascular Intervention

Devices for Vascular Interventions offers atherectomy systems for removal of plaque from coronary arteries

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.